Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

por Kamm, M A, Lichtenstein, G R, Sandborn, W J, Schreiber, S, Lees, K, Barrett, K, Joseph, R
Publicado 2008

Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease

por Vande Casteele, N., Feagan, B. G., Vermeire, S., Yassine, M., Coarse, J., Kosutic, G., Sandborn, W. J.
Publicado 2017

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies

por Sandborn, W. J., Danese, S., D'Haens, G., Moro, L., Jones, R., Bagin, R., Huang, M., David Ballard, E., Masure, J., Travis, S.
Publicado 2015

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE

por Panaccione, R, Colombel, J-F, Sandborn, W J, D'Haens, G, Zhou, Q, Pollack, P F, Thakkar, R B, Robinson, A M
Publicado 2013

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

por Rosario, M., Dirks, N. L., Gastonguay, M. R., Fasanmade, A. A., Wyant, T., Parikh, A., Sandborn, W. J., Feagan, B. G., Reinisch, W., Fox, I.
Publicado 2015

Randomised clinical study: discrepancies between patient‐reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis

por Jharap, B., Sandborn, W. J., Reinisch, W., D'Haens, G., Robinson, A. M., Wang, W., Huang, B., Lazar, A., Thakkar, R. B., Colombel, J.‐F.
Publicado 2015

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventiona...

por Colombel, J.‐F., Jharap, B., Sandborn, W. J., Feagan, B., Peyrin‐Biroulet, L., Eichner, S. F., Robinson, A. M., Mostafa, N. M., Zhou, Q., Thakkar, R. B.
Publicado 2016

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

por Sandborn, W. J., Rutgeerts, P., Gasink, C., Jacobstein, D., Zou, B., Johanns, J., Sands, B. E., Hanauer, S. B., Targan, S., Ghosh, S., de Villiers, W. J. S., Colombel, J.‐F., Feagan, B. G.
Publicado 2018

Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis

por Rutgeerts, P., Feagan, B. G., Marano, C. W., Padgett, L., Strauss, R., Johanns, J., Adedokun, O. J., Guzzo, C., Zhang, H., Colombel, J.‐F., Reinisch, W., Gibson, P. R., Sandborn, W. J.
Publicado 2015

Adalimumab for the treatment of fistulas in patients with Crohn’s disease

por Colombel, J-F, Schwartz, D A, Sandborn, W J, Kamm, M A, D’Haens, G, Rutgeerts, P, Enns, R, Panaccione, R, Schreiber, S, Li, J, Kent, J D, Lomax, K G, Pollack, P F
Publicado 2009

Randomised clinical trial: a phase 1, dose‐ranging study of the anti‐matrix metalloproteinase‐9 monoclonal antibody GS‐5745 versus placebo for ulcerative colitis

por Sandborn, W. J., Bhandari, B. R., Fogel, R., Onken, J., Yen, E., Zhao, X., Jiang, Z., Ge, D., Xin, Y., Ye, Z., French, D., Silverman, J. A., Kanwar, B., Subramanian, G. M., McHutchison, J. G., Lee, S. D., Shackelton, L. M., Pai, R. K., Levesque, B. G., Feagan, B. G.
Publicado 2016